Morten Graugaard Døssing

Morten Graugaard Døssing currently serves as Chairman of the Board at Orbis Medicines and as a Member of the Board of Directors at Muna Therapeutics and NMD Pharma, a Novo Holdings portfolio company focused on orphan neuromuscular diseases. As a Partner and Investment Director at Novo Holdings, Morten is involved with Novo Seeds, which supports early-stage life science projects in Scandinavia and Europe. Morten also holds board positions at several other companies, including Hyperbio Therapeutics, Stipe Therapeutics, and Camel-IDS. Educational qualifications include a Master of Science in Human Biology from the University of Copenhagen and multiple diplomas in executive leadership and medical innovation from various prestigious institutions.